The gene that encodes human epidermal growth factor receptor 2 (HER2) is amplified or overexpressed in approximately 15–20% of invasive breast cancer cases and historically associated with an increased risk of disease recurrence and overall worse prognosis than HER2-negative breast cancer [1, 2]. Here, ERBB2 is linked to invasive breast carcinoma.